Laura Dawson, MD, FRCPC, professor, Department of Radiation Oncology, University of Toronto, discusses screening and prevention of hepatocellular carcinoma (HCC).
Brexu-cel Achieves Strong CNS and Systemic Responses in Adult B-ALL Patients
Ibrahim N. Muhsen, MD, evaluated the efficacy of brexu-cel in adult patients with central nervous system involvement in relapsed/refractory B-cell acute lymphoblastic leukemia.
Read More
Tailoring Treatments to Better Outcomes in Liver Cancer
In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.
Listen
Improving Outcomes Using Ribociclib in High-Risk Node-Negative Breast Cancer
Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node involvement who were enrolled in the phase 3 NATALEE trial.
Optimizing Treatment in Myeloma With Biweekly Dosing of Talquetamab
Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple myeloma.
Balancing Clinical Data and Real-World Insights in CML Treatment
In an interview with Targeted Oncology, Michael Mauro, MD, delved into the rapidly advancing field of chronic myeloid leukemia treatment.
FDA OKs Study of Amezalpat in Frontline Liver Cancer
The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic hepatocellular carcinoma.